胰腺癌是起病隐匿、进展迅速、预后很差的消化道恶性肿瘤。中位生存期仅5个月,5年生存率<5%~([1])。超过80%的病人在就诊时为晚期而无法手术切除~([2])。即使能手术切除,中位生存期也仅为18个月~([3])。目前化疗仍是胰腺癌重要的辅助治疗手段之一。吉西他滨是治疗进展期胰腺癌的一线方案,但最新研究表明,多数胰腺癌病人也逐渐对吉西他滨 Pancreatic cancer is occult onset, rapid progress, poor prognosis of gastrointestinal cancer. The median survival was only 5 months, 5-year survival rate was <5% ~ ([1]). More than 80% of patients are late and can not be surgically removed at the time of their visit ~ ([2]). The median survival is only 18 months ~ ([3]), even when surgically resected. At present, chemotherapy is still one of the important adjuvant treatments for pancreatic cancer. Gemcitabine is the first-line treatment of advanced pancreatic cancer program, but the latest research shows that the majority of pancreatic cancer patients are gradually gemcitabine